The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto ® or Stiolto ® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the lon...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-04-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/1753466619843426 |
| _version_ | 1828432207732015104 |
|---|---|
| author | Eric Derom Guy G. Brusselle Guy F. Joos |
| author_facet | Eric Derom Guy G. Brusselle Guy F. Joos |
| author_sort | Eric Derom |
| collection | DOAJ |
| description | Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto ® or Stiolto ® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenoceptor agonist olodaterol (OLO), formulated in the Respimat ® Soft Mist™ inhaler. A total of 13 large, multicentre studies of up to 52 weeks’ duration have documented its efficacy in more than 15,000 patients with COPD. TIO/OLO 5/5 µg FDC significantly increases pulmonary function compared with placebo and its respective constituent mono-components TIO 5 µg and OLO 5 µg. TIO/OLO 5/5 µg also results in statistically and clinically significant improvements in patient-reported outcomes, such as dyspnoea, use of rescue medication, and health status. Addition of OLO 5 µg to TIO 5 µg reduces the rate of moderate-to-severe exacerbations by approximately 10%. Compared with placebo and TIO 5 µg, TIO/OLO 5/5 µg significantly improves exercise capacity (e.g. endurance time) and physical activity, the latter increase being reached by a unique combination behavioural modification intervention, dual bronchodilatation and exercise training. Overall, the likelihood for patients to experience a clinically significant benefit is higher with TIO/OLO 5/5 µg than with its constituent mono-components, which usually yield smaller improvements which do not always reach statistical significance, compared with baseline or placebo. This supports the early introduction of TIO/OLO 5/5 µg in the management of patients with symptomatic COPD. |
| first_indexed | 2024-12-10T18:16:48Z |
| format | Article |
| id | doaj.art-d5be362ae61f41a1a400e046ace277ed |
| institution | Directory Open Access Journal |
| issn | 1753-4666 |
| language | English |
| last_indexed | 2024-12-10T18:16:48Z |
| publishDate | 2019-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Respiratory Disease |
| spelling | doaj.art-d5be362ae61f41a1a400e046ace277ed2022-12-22T01:38:19ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662019-04-011310.1177/1753466619843426The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospectsEric DeromGuy G. BrusselleGuy F. JoosLong-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto ® or Stiolto ® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenoceptor agonist olodaterol (OLO), formulated in the Respimat ® Soft Mist™ inhaler. A total of 13 large, multicentre studies of up to 52 weeks’ duration have documented its efficacy in more than 15,000 patients with COPD. TIO/OLO 5/5 µg FDC significantly increases pulmonary function compared with placebo and its respective constituent mono-components TIO 5 µg and OLO 5 µg. TIO/OLO 5/5 µg also results in statistically and clinically significant improvements in patient-reported outcomes, such as dyspnoea, use of rescue medication, and health status. Addition of OLO 5 µg to TIO 5 µg reduces the rate of moderate-to-severe exacerbations by approximately 10%. Compared with placebo and TIO 5 µg, TIO/OLO 5/5 µg significantly improves exercise capacity (e.g. endurance time) and physical activity, the latter increase being reached by a unique combination behavioural modification intervention, dual bronchodilatation and exercise training. Overall, the likelihood for patients to experience a clinically significant benefit is higher with TIO/OLO 5/5 µg than with its constituent mono-components, which usually yield smaller improvements which do not always reach statistical significance, compared with baseline or placebo. This supports the early introduction of TIO/OLO 5/5 µg in the management of patients with symptomatic COPD.https://doi.org/10.1177/1753466619843426 |
| spellingShingle | Eric Derom Guy G. Brusselle Guy F. Joos The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects Therapeutic Advances in Respiratory Disease |
| title | The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects |
| title_full | The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects |
| title_fullStr | The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects |
| title_full_unstemmed | The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects |
| title_short | The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects |
| title_sort | once daily fixed dose combination of olodaterol and tiotropium in the management of copd current evidence and future prospects |
| url | https://doi.org/10.1177/1753466619843426 |
| work_keys_str_mv | AT ericderom theoncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects AT guygbrusselle theoncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects AT guyfjoos theoncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects AT ericderom oncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects AT guygbrusselle oncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects AT guyfjoos oncedailyfixeddosecombinationofolodaterolandtiotropiuminthemanagementofcopdcurrentevidenceandfutureprospects |